Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
REGULATORY
MHLW to Run Pilot Sale of Emergency Contraceptives without Prescription
The Ministry of Health, Labor and Welfare (MHLW) will deploy a pilot program for the sale of emergency contraceptives without a prescription, starting from as early as this summer to the end of next March. The MHLW unveiled this plan…
To read the full story
Related Article
- Purchasers Satisfied, Pharmacy Service “Appropriate” in Non-Prescription Pilot for Emergency Contraceptives
May 14, 2024
- Citizens’ Group Opposes Pilot Switch Program for Emergency Contraceptives
June 27, 2023
- Will Pilot Switch Proposal Break Stalemate in Emergency Contraceptive Debate?
June 23, 2023
- MHLW Mulls New OTC Class to Bar Online Sales amid Unease over Morning After Pills
June 14, 2023
- LDP Lawmakers Oppose Online Sale of Morning After Pills 3 Years after Switch
June 8, 2023
- Japan Eyes Pilot Program for OTC-Switching of Emergency Contraceptives, Public Commenters Overwhelmingly Positive
May 18, 2023
- MHLW Taking Public Comments on OTC Access to Emergency Contraceptives
January 6, 2023
- Rx-to-OTC Switching of Morning After Pills Needs Cautious Approach: Lawmakers
December 27, 2022
- MHLW to Reexamine Whether to Permit Sale of Emergency Contraceptives Without a Prescription
October 12, 2020
- OTC Switching of Emergency Contraceptive Levonorgestrel Will Be Difficult Under Current System: JPA
October 16, 2017
- MHLW Council Recommends Switching of 4 APIs; Switching of Levonorgestrel for Emergency Contraception Disapproved
July 28, 2017
REGULATORY
- Japan Likely to Extend “Catch-Up” HPV Vaccination Program
November 26, 2024
- As 2025 Budgeting Nears, “No” to Off-Year Revisions Arises from LDP Too
November 26, 2024
- Japan Gets Down to the Business of Solving Drug Loss, New Scheme Begins with 78 Meds
November 26, 2024
- MHLW Proposes Upping Copay Limits in High-Cost Medical Expense Scheme
November 25, 2024
- Japan’s New Economic Package Covers Pharma-Related Steps, but Not Repeal of Off-Year Revisions
November 25, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…